

# Invitation

## Transforming the Treatment of MS – New Measures and Mechanisms

Chairs: Hans-Peter Hartung (Germany)  
and Jeffrey Cohen (USA)

Thursday 10 September 2009  
*Düsseldorf, Germany*

This programme is not part of the official Congress of the European Committee  
for Treatment and Research in Multiple Sclerosis

# Welcome

## Dear Colleague

It is our pleasure to invite you to this satellite symposium entitled *'Transforming the Treatment of MS – New Measures and Mechanisms'*, organised by Novartis in Düsseldorf on Thursday 10 September 2009.

During this symposium, our panel of distinguished experts will present recent data on a novel drug class which targets MS via actions in both the immune and central nervous system (CNS), discuss new imaging measures, and provide an update on the Novartis clinical programme in MS.

Professor Jerold Chun will begin the session by presenting new data implicating sphingosine 1-phosphate (S1P) receptor biology in MS pathology. He will then describe how modulation of these receptors on lymphocytes and neural cells translates into beneficial effects in animal models of MS and possible benefits for patients with MS.

With the emergence of new molecules which target the CNS, such as S1P receptor modulators, there is a need for techniques that allow us to measure treatment effects in the CNS. In the second talk, Professor Frederik Barkhof will provide an assessment of emerging imaging techniques that may enable measurement of neuroprotection and repair in MS trials.

In the final talk, Professor Ludwig Kappos will present an overview of the ongoing Novartis Phase II/III clinical programme in MS. This will include a discussion of the novel methodology and approaches used in the Phase III study design, and an overview of a large Phase III study in primary progressive MS.

We hope you will enjoy this European congress and look forward to welcoming you to what promises to be a stimulating and informative symposium.



**Professor Hans-Peter Hartung**



**Professor Jeffrey Cohen**

# Programme

## Transforming the Treatment of MS – New Measures and Mechanisms

*Chairs: Hans-Peter Hartung (Germany) and Jeffrey Cohen (USA)*

Thursday 10 September 2009

12:45-13:45

12:45-12:50 **Introduction**

Jeffrey Cohen  
(USA)

12:50-13:10 **Talk 1. New mechanisms in MS – targeting the S1P receptor**

Jerold Chun  
(USA)

13:10-13:25 **Talk 2. New measures for assessing neuroprotection and repair in MS**

Frederik Barkhof  
(The Netherlands)

13:25-13:40 **Talk 3. Transforming MS treatment – the oral fingolimod clinical programme**

Ludwig Kappos  
(Switzerland)

13:40-13:45 **Q&A and concluding remarks**

Hans-Peter Hartung  
(Germany)



